Stoke Therapeutics (NASDAQ:STOK) Insider Sells $174,200.00 in Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Arthur Tzianabos sold 4,355 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $40.00, for a total transaction of $174,200.00. Following the sale, the insider directly owned 31,339 shares in the company, valued at $1,253,560. This trade represents a 12.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $33.19 on Friday. The firm has a 50-day moving average of $32.71 and a two-hundred day moving average of $29.63. The stock has a market cap of $1.90 billion, a P/E ratio of 49.54 and a beta of 1.07. Stoke Therapeutics, Inc. has a 1-year low of $5.35 and a 1-year high of $40.22.

Institutional Trading of Stoke Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the company. AQR Capital Management LLC lifted its holdings in Stoke Therapeutics by 1.2% during the 4th quarter. AQR Capital Management LLC now owns 29,467 shares of the company’s stock worth $935,000 after buying an additional 354 shares during the last quarter. Strs Ohio increased its holdings in shares of Stoke Therapeutics by 9.4% in the 4th quarter. Strs Ohio now owns 7,000 shares of the company’s stock valued at $222,000 after acquiring an additional 600 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Stoke Therapeutics by 31.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock valued at $88,000 after acquiring an additional 658 shares during the last quarter. Generali Investments Management Co LLC raised its position in shares of Stoke Therapeutics by 41.0% during the 4th quarter. Generali Investments Management Co LLC now owns 2,471 shares of the company’s stock valued at $78,000 after acquiring an additional 718 shares in the last quarter. Finally, Kestra Advisory Services LLC bought a new position in Stoke Therapeutics during the fourth quarter worth $26,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Wolfe Research assumed coverage on Stoke Therapeutics in a report on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target for the company. Canaccord Genuity Group upped their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the company a “buy” rating in a research report on Monday, January 5th. UBS Group set a $50.00 target price on Stoke Therapeutics in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Finally, Chardan Capital lifted their price target on shares of Stoke Therapeutics from $24.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.25.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.